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Prolonged Small Bowel Graft Survival Using Photochemotherapy and 
Low-Dose FK 506 
Y. Toyama, N. Murase, F.H.F. Galvao, T. Sakamoto, M. Nomoto, T.E. Starzl, and S. Todo 
WHILE immunosuppressive therapy for organ trans-plantation improved greatly, rejection remains a 
major obstacle to successful small bowel transplantation 
(SBTx).l Photochemotherapy (PCT), the combination of 
ultraviolet A (UV A) irradiation and the photosensitizing 
agent, 8-methoxypsoralen (8-MOP), has been reported to 
be effective in inhibiting in vitro and in vivo responses to 
alloantigens.2 When added to conventional immunosup-
pressive therapy, PCT has been shown to reduce the 
number of acute or recurrent rejection episodes in heart 
transplant patients.3 This study investigated the efficacy of 
PCT in preventing allograft rejection after SBTx. 
MATERIALS AND METHODS 
Inbred male ACI (RTla ) and LEW (RTl') rats weighing 200 to 300 g 
were used as donors and recipients. respectively. Orthotopic SBT with 
portocaval drainage was performed as previously described.4 The 
recipients were divided into five groups: group 1 (n = 6) were 
untreated controls; group 2 (n = 6) received 100 x lQ'i PCf-treated 
splenocytes on day 3; group 3 (n = 17) received low-dose intramus-
cular (1M) FK 506 (0.5 m/Y'kg/d) for 2 postoperative weeks; group 4 
(n = 13) received 100 x lQ'i PCf-untreated splenocytes on day 3 plus 
the 2-week course of low-dose FK 506; group 5 (n = 24) received 
100 x lQ'i PCf-treated splenocytes on day 3 and the 2-week course of 
low-dose FK 506. Splenocytes transfused into the recipients in groups 
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2, 4, and 5 were obtained by killing other low-dose FK 506-treated 
LEW recipients of ACI small bowel grafts 3 days after transplantation. 
Splenocytes in groups 2 and 5 were treated by 8-MOP (100 ng/mL) for 
20 minutes and exposed to UVA (1 J/cm2, Therakos, Inc, West 
Chester, Pal. 
RESULTS 
Untreated recipients (group 1) died in 7 days (Fig 1). 
Infusion of PCT -treated splenocytes into SBTx recipients 
was not effective by itself, with a median survival of 8 days 
(group 2). Low-dose FK 506 treatment slightly improved 
graft survival to 17 days without splenocyte infusion (group 
3; P < .05 vs group 1, Mann-Whitney U test) and 15 days 
with PCf-untreated splenocytes (group 4; P < .01). Small 
bowel graft survival was significantly improved to 86 days in 
group 5, when recipients were treated with low-dose FK 506 
and PCT-treated splenocytes (P < .005). Seven of 24 
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animals in this group survived for more than 100 days. 
Histopathologic examination of these long-surviving small 
bowel grafts revealed chronic rejection. 
DISCUSSION 
This study shows that the combination of PCf with a 
subtherapeutic dose of FK 506 is effective in prolonging 
graft survival after SBTx. PCf has been successfully used 
for the treatment of autoimmune diseases and cutaneous 
T -cell lymphoma. However, application of this treatment in 
the field of transplantation is still preliminary. 
The mechanism involved in this treatment is not clearly 
defined. The splenocytes we used for PCf treatment con-
tained 2.7 ::!: 0.3% donor phenotype cells with a slightly 
lower CD4/CD8 ratio (1.8), compared to LEW-LEW 
isograft recipients (2.2). These splenocytes proliferated 
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strongly in mixed lymphocyte reaction (MLR) to donor and 
third-party (PVG) lymphocytes and showed vigorous spon-
taneous proliferation in medium. These preliminary obser-
vations may suggest that activated allogeneic cells play an 
important role in Pcf treatment of allograft recipients. 
Further studies to clarify the mechanism of this treatment 
are needed. 
REFERENCES 
1. Todo S, Tzakis A, Reyes J, et al: Transplant Proc 26:1409, 
1994 
2. Yamane y, Lobo FM, John LA, et a1: Transplantation 54:119, 
1992 
3. Dall' Amico R, Livi U, Milano A, et al: Transplantation 60:45, 
1995 
4. Murase N, Demetris AI, Kim DG, et al: Surgery 108:880, 
1990 
I 
